Technical Information

Ravgen’s core technology is based on its ability to increase the percentage of fetal DNA that is found in the mother’s blood.  Through its research with free floating fetal DNA, the company has developed and patented a variety of noninvasive prenatal tests that simply require a safe blood draw from the mother.

Publications

Ravgen’s work has been published in widely recognized and internationally accepted, peer reviewed journals. View our publications on noninvasive fetal DNA testing by clicking on the images to the right. Ravgen has been published in many medical publications such as: The New England Journal of MedicineThe Lancet and The Journal of the American Medical Association.

You can also visit the news page to see other publications that Ravgen has been published in.

nejm
New England Journal
of Medicine

PDF

lancet
The Lancet

WEB

JAMA
The Journal of the American Medical Association

WEB

Leadership

Dr. Ravinder Dhallan, founder of Ravgen

Dr. Dhallan has extensive and diverse training in biomedical engineering, clinical research, and medicine, and has published numerous articles on genetic research in widely recognized and internationally accepted peer-reviewed journals. Dr. Dhallan has not only provided leadership for Ravgen’s business strategy but is also the inventor of Ravgen’s proprietary technology. Prior to founding Ravgen in September of 2000, Dr. Dhallan was a residency-trained, board-certified emergency room physician. Dr. Dhallan earned his M.D. and Ph.D. from The Johns Hopkins University School of Medicine in Baltimore, Maryland, and his MBA from The Wharton School of Business at the University of Pennsylvania.